A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging

Forest Laboratories

Status and phase: Terminated; Phase 2

Conditions: Ischemic Heart Disease; Cardiovascular Disease

Treatments: Drug: apadenoson

Study type: Interventional

Funder types: Industry

Identifiers

NCT00162071

BMS068645-203

Details and patient eligibility

About

The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age or older
• Have known or suspected heart disease
• Have undergone a clinically indicated SPECT MPI study with adenosine in the last 24 hours to 14 days.
• Weigh between 88 and 250 lbs.

Exclusion criteria

• Allergic reaction to Technetium Tc99m Sestamibi or any of its components
• History of asthma or lung disease
• Ingestion of caffeinated substances within 12 hours prior to the study

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)